Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Myelodysplastic Syndrome News

News
Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS
10/30/2023
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.
Molecular scoring system IPSS-M...
10/30/2023
Oncology
News
FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation
10/26/2023
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA...
10/26/2023
Oncology

Advertisement

News
CPX-351 vs FLAG-Ida Treatment for Patients With Adverse Karyotype AML/High-Risk MDS
09/29/2023
The overall survival of younger patients with adverse risk AML/MDS was not significantly different between treatment with CPX-351 or FLAG-Ida, according to findings from the UK NCRI AML19 trial.
The overall survival of younger patients with adverse risk AML/MDS was not significantly different between treatment with CPX-351 or FLAG-Ida, according to findings from the UK NCRI AML19 trial.
The overall survival of younger...
09/29/2023
Oncology
News
Triplet Combination Yields Encouraging Activity for Newly Diagnosed Secondary AML, MDS, or CMML After Failure of Hypomethylating Agents
09/27/2023
The combination of azacitidine, venetoclax, and pevonedistat yielded encouraging efficacy among a poor-risk population of patients with AML, MDS or CMML, according to a phase 1/2 trial.
The combination of azacitidine, venetoclax, and pevonedistat yielded encouraging efficacy among a poor-risk population of patients with AML, MDS or CMML, according to a phase 1/2 trial.
The combination of azacitidine,...
09/27/2023
Oncology
News
Eltrombopag Demonstrated Efficacy, Relative Safety Among Patients With Low-Risk MDS and Severe Thrombocytopenia
09/20/2023
Eltrombopag demonstrated efficacy and relative safety among patients with low-risk myelodysplastic syndromes and severe thrombocytopenia, according to the phase 2 EQOL-MDS trial.
Eltrombopag demonstrated efficacy and relative safety among patients with low-risk myelodysplastic syndromes and severe thrombocytopenia, according to the phase 2 EQOL-MDS trial.
Eltrombopag demonstrated...
09/20/2023
Oncology

Advertisement

News
Evaluating Long-Term Clinical Efficacy of ESAs Among Patients With Low‑Risk or Intermediate‑1‑Risk MDS
09/11/2023
Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...
Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...
Erythropoiesis‑stimulating agent...
09/11/2023
Oncology
News
Analysis of Real-World Outcomes in First-Line Treatment Among Patients With Myelodysplastic Syndromes
09/08/2023
Improved first-line clinical strategy for treating patients with lower-risk MDS would be beneficial, according to a global, retrospective study presented at the Society of Hematologic Oncology 2023 Annual Meeting.
Improved first-line clinical strategy for treating patients with lower-risk MDS would be beneficial, according to a global, retrospective study presented at the Society of Hematologic Oncology 2023 Annual Meeting.
Improved first-line clinical...
09/08/2023
Oncology
News
Transfusion Burden Decrease, Hemoglobin Increase With Luspatercept vs Epoetin Alfa Treatment for ESA‑Naive Patients With Transfusion‑Dependent Lower‑Risk MDS
09/08/2023
Luspatercept demonstrated multiple clinical benefits for ESA-naive patients with transfusion-dependent lower-risk MDS, including hemoglobin increases and transfusion-burden decreases, according to research presented at the SOHO 2023 Annual...
Luspatercept demonstrated multiple clinical benefits for ESA-naive patients with transfusion-dependent lower-risk MDS, including hemoglobin increases and transfusion-burden decreases, according to research presented at the SOHO 2023 Annual...
Luspatercept demonstrated...
09/08/2023
Oncology

Advertisement

News
G-CSF Plus Decitabine and Busulfan-Cyclophosphamide Conditioning for Patients With MDS-RAEB and Secondary AML Evolving From MDS
05/11/2023
According to a phase 3 trial, a granulocyte-colony stimulating factor plus decitabine and busulfan-cyclophosphamide conditioning regimen reduced the incidence of relapse among patients with MDS refractory anemia with excess blasts and...
According to a phase 3 trial, a granulocyte-colony stimulating factor plus decitabine and busulfan-cyclophosphamide conditioning regimen reduced the incidence of relapse among patients with MDS refractory anemia with excess blasts and...
According to a phase 3 trial, a...
05/11/2023
Oncology
News
Magrolimab and Azacitidine Combination Treatment for Patients With Untreated High-Risk MDS
04/28/2023
According to a phase 1b trial, magrolimab and azacitidine combination treatment yielded safe and effective results among patients with untreated high-risk myelodysplastic syndromes.
According to a phase 1b trial, magrolimab and azacitidine combination treatment yielded safe and effective results among patients with untreated high-risk myelodysplastic syndromes.
According to a phase 1b trial,...
04/28/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use